Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
Bijal Shah(Boston College), Olalekan O. Oluwole(Vanderbilt University), Patrick J. Stiff(Loyola University Medical Center), Martha Arellano(Memorial Sloan Kettering Cancer Center), Mehrdad Abedi(UC Davis Comprehensive Cancer Center), Tsveta Hadjivassileva, Deepa Jeyakumar(Dana-Farber Cancer Institute), Lang Zhou(Kite (United States)), Roch Houot(Inserm), Gary J. Schiller(Fred Hutch Cancer Center), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Daqin Mao(Tufts Medical Center), Monique C. Minnema(University Medical Center Utrecht), Maria R. Baer(University of Maryland, Baltimore), Aaron C. Logan(University of California, San Francisco), Ryan D. Cassaday(University of Washington), Nicolas Boissel(Inserm), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Armin Ghobadi(Washington University in St. Louis), William G. Wierda(University of Maryland, Baltimore), Michael R. Bishop(University of Chicago), Yi Lin, Max S. Topp(Universitätsklinikum Würzburg), Jae H. Park(Memorial Sloan Kettering Cancer Center), Sabina Adhikary(Kite (United States)), Marion Subklewe(LMU Klinikum), Rita Damico Khalid, Kristen M. O’Dwyer(University of Rochester Medical Center)
Cited by 35
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k